ArticleFrontiers in medicine2026
Development of a CT-based comprehensive model with deep learning for differentiating pathological types of pulmonary ground-glass nodules.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lack of reliable clinical features for differentiating benign from malignant pulmonary pure ground-glass nodules (pGGNS) leads to potential misdiagnosis and unnecessary invasive examinations. Although radiomics and deep learning approaches have shown potential in nodule characterization, the diagnostic performance of integrated models combining clinical features, radiomics, and deep learning remains insufficiently defined. This study aimed to develop and validate an integrated model to distinguish benign from malignant pGGNs and to further differentiate pathological subtypes. Materials and methods: This retrospective study included 1,067 patients with pulmonary pGGNs from Shandong First Medical University Cancer Hospital. Clinical and imaging data were collected, and radiomics features and deep learning (DL) derived features were extracted using Python (version 3.7). Patients were randomly divided into training and validation cohorts. Multiple machine-learning classifiers were constructed, and diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis. Results: For distinguishing benign from malignant pGGNS (Model 1), clinical features such as age, nodule multiplicity, CEA levels, and amylase were identified as clinically relevant features. Thirty-eight valuable features were selected for model development. Among individual classifiers, the Support Vector Machine (SVM) achieved the highest performance with a validation receiver operating characteristic curve (AUC) of 0.840, followed by random forest (0.829), stochastic gradient descent (0.828), k-nearest neighbors (0.814), XGBoost (0.798), and LightGBM (0.818). The integrated model combining clinical features, radiomics, and deep learning achieved a validation set AUC of 0.871. For pathological subtype classification of pGGNs (Model II), clinical features such as gender, Pro-Gastrin-Releasing-Peptide (ProGRP), AST/ALT ratio (De Ritis ratio), creatine kinase-MB (CKMB), and globulin were identified as informative clinical variables. Twelve valuable features were selected The SVM classifier again showed the best individual performance (validation AUC = 0.831), while the integrated model achieved a superior AUC of 0.853. Conclusion: An integrated model incorporating clinical characteristics, radiomics, and deep learning demonstrates robust performance in distinguishing benign from malignant pulmonary pGGNs and in identifying pathological subtypes, suggesting potential clinical utility for non-invasive decision support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.